Gubra
Business Services · Denmark · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Hørsholm Kongevej 11b, Korsholm, North D...Phone Number
+45 31522650Website
www.gubra.dkRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Gubra
Gubra specializes in high-end preclinical contract research and peptide-based drug discovery, focusing on metabolic and fibrotic diseases. Their services include advanced modeling and technologies for drug development, particularly in areas such as obesity, diabetes, and kidney diseases. Gubra partners with various organizations to enhance drug discovery and development, leveraging their expertise in peptide therapeutics. The company is committed to sustainability and invests in green initiatives to contribute to a more sustainable future.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gubra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Gubra has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Gubra launches new products
Check if Gubra has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Gubra recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Gubra
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Gubra had a recent Job posting/layoffs
Gubra, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Gubra is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Gubra is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Gubra is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Gubra.
Gubra Tech Stack
A closer look at the technologies used by Gubra
Most Recent Scoops
Project
Gubra has announced that cardiorenal endpoints will be collected during the multiple dose part of the ongoing GUB-UCN2 clinical trial, with the resulting data set, in conjunction with preclinical profiling, to determine the direction of further UCN2 development.
Medical Research, Clinical Operations
Earnings
Gubra has reported milestone payments of DKK 30 million in H1 2026, compared to the DKK 2.4 billion AbbVie upfront payment received in the prior year, with an additional EUR 10 million milestone from Boehringer Ingelheim recognized in Q3 2026 upon the initiation of Phase II for the triple agonist.
Earnings, Pharmaceuticals, Finance
Earnings
Gubra has maintained its unchanged 2026 outlook, with Biotech total costs guidance of DKK 330 to 360 million, CRO revenue growth of 0% to 10%, and a CRO EBIT margin of 10% to 15%.
Earnings, Finance
Project
Gubra has reported preclinical data demonstrating that GUB-UCN2 profoundly reduces fat mass and builds lean muscle mass in obese rats, and when combined with semaglutide, produces an additive effect on fat mass reduction while preserving muscle mass lost with semaglutide monotherapy.
Earnings
Business Development, Forecasting, Corporate Strategy
Gubra News & Media
Gubra A/S (GUBRF) Q1 2026 Earnings Call Transcript
Gubra A/S (GUBRF) Q1 2026 Earnings Call May 6, 2026 4:00 AM EDTCompany ParticipantsMarkus Rohrwild - Chief Executive OfficerLouise Dalboge - Chief Science...Gubra re-elects board of directors - MedWatch
Monika Lessl will thus continue as chair of the Danish biotech company.Gubra recruits former Novo Nordisk director as new CTO - MedWatch
Gubra’s new chief technology officer was until recently senior director at Novo Nordisk.Denmark: Abbvie enters obesity field with license agreement with Gubra
Denmark: Abbvie enters obesity field with license agreement with Gubra
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Gubra
Sign Up For FreeTo access detailed company insights
Gubra specializes in high-end preclinical contract research and peptide-based drug discovery, focusing on metabolic and fibrotic diseases. Their services include advanced modeling and technologies for drug development, particularly in areas such as obesity, diabetes, and kidney diseases. Gubra partners with various organizations to enhance drug dis... Read More
